PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections

Area of Science:

• Pulmonary mycology
• Antifungal drug development
• Respiratory medicine

Background:

• Pulmonary Aspergillus infections pose a significant challenge, especially in immunocompromised individuals.
• Current inhaled antifungal treatments primarily repurpose systemic medications.
• There is a need for novel inhaled antifungals with high local lung concentrations and minimal systemic exposure.

Purpose of the Study:

• To evaluate the efficacy and safety of PC945, a novel inhaled triazole antifungal agent.
• To assess PC945's pharmacokinetic profile and tolerability in healthy volunteers, asthmatics, and lung transplant patients.
• To investigate PC945's activity against Aspergillus and Candida species, including resistance development and combination therapy potential.

Main Methods:

• Preclinical in vitro and in vivo testing of PC945 against Aspergillus and Candida species.
• Pharmacokinetic and safety assessment in healthy volunteers and asthmatics via nebulized administration.
• Case study of PC945 treatment in two lung transplant patients with invasive pulmonary Aspergillus infection.

Main Results:

• PC945 demonstrated potent antifungal activity against Aspergillus and Candida species.
• Antifungal effects against Aspergillus fumigatus accumulated with repeat dosing and showed enhanced efficacy in combination therapy.
• Nebulized PC945 was well tolerated in healthy volunteers and asthmatics with limited systemic exposure and long lung residency.
• PC945 successfully treated invasive pulmonary Aspergillus infection in two lung transplant patients unresponsive to other antifungals, without systemic side effects.

Conclusions:

• PC945 is a promising novel inhaled antifungal agent for pulmonary Aspergillus infections.
• Its favorable safety profile, high local lung concentration, and efficacy in difficult-to-treat cases warrant further investigation.
• PC945 offers a potential new therapeutic option for invasive pulmonary fungal diseases, particularly in vulnerable patient populations.